Drug Interaction Report

The sodium benzoate in Ammonul has a moderate potential interaction with Acidosis.

Sodium benzoate is structurally similar to salicylates and mild respiratory alkalosis may occur. Therapy with sodium benzoate should be administered cautiously in patients with or predisposed to respiratory acidosis.

The sodium phenylacetate in Ammonul has a moderate potential interaction with Autonomic Neuropathy.

The administration of intravenous phenylacetate may cause neurotoxicity. It is recommended to exercise care when using products containing sodium phenylacetate and sodium benzoate in cancer patients or in patients with neurotoxic disorders.

The sodium benzoate in Ammonul has a major potential interaction with Fluid Retention.

Sodium chloride can induce sodium and water retention and result in hypernatremia, hypokalemia, edema and aggravation of congestive heart failure. Therapy with sodium- containing agents should be administered with extreme caution, if at all, in patients with congestive heart failure, severe renal insufficiency, and in clinical states where there is edema with sodium retention. Clinical monitoring of acid/base balance and electrolytes prior to, during, a following completion of therapy with sodium- containing agents is recommended.

The sodium benzoate in Ammonul has a major potential interaction with Heart Failure.

Sodium chloride can induce sodium and water retention and result in hypernatremia, hypokalemia, edema and aggravation of congestive heart failure. Therapy with sodium- containing agents should be administered with extreme caution, if at all, in patients with congestive heart failure, severe renal insufficiency, and in clinical states where there is edema with sodium retention. Clinical monitoring of acid/base balance and electrolytes prior to, during, a following completion of therapy with sodium- containing agents is recommended.

The sodium phenylacetate in Ammonul has a moderate potential interaction with Heart Failure.

The combination product of sodium phenylacetate and sodium benzoate injection 10%/10% contains 30.5 mg of sodium per mL of undiluted product. Sodium phenylacetate and sodium benzoate injection should be used with great care, if at all, in patients with congestive heart failure or severe renal insufficiency, and in clinical states in which there is sodium retention with edema. It is recommended to discontinue administration of sodium phenylacetate and sodium benzoate injection, 10%/10%, evaluate the patient, and institute appropriate therapeutic countermeasures as appropriate.

The sodium benzoate in Ammonul has a major potential interaction with Hypernatremia.

Sodium chloride can induce sodium and water retention and result in hypernatremia, hypokalemia, edema and aggravation of congestive heart failure. Therapy with sodium- containing agents should be administered with extreme caution, if at all, in patients with congestive heart failure, severe renal insufficiency, and in clinical states where there is edema with sodium retention. Clinical monitoring of acid/base balance and electrolytes prior to, during, a following completion of therapy with sodium- containing agents is recommended.

The sodium benzoate in Ammonul has a major potential interaction with Hypokalemia.

Sodium chloride can induce sodium and water retention and result in hypernatremia, hypokalemia, edema and aggravation of congestive heart failure. Therapy with sodium- containing agents should be administered with extreme caution, if at all, in patients with congestive heart failure, severe renal insufficiency, and in clinical states where there is edema with sodium retention. Clinical monitoring of acid/base balance and electrolytes prior to, during, a following completion of therapy with sodium- containing agents is recommended.

The sodium phenylacetate in Ammonul has a moderate potential interaction with Hypokalemia.

Potassium levels should be carefully monitored as the excretion of the non-reabsorbable anions, phenylacetylglutamine and hippurate can enhance urine potassium loss. Care should be taken when using products containing sodium phenylacetate and sodium benzoate in patients with low blood potassium levels.

Iloprost has a major potential interaction with Hypotension.

Iloprost should not be initiated in patients with systolic blood pressure below 85 mmHg. The risk of syncope in association with physical exertion can occur in pulmonary arterial hypertension and the occurrence may reflect a therapeutic gap or insufficient efficacy. The need to adjust dose or change therapy should be considered. It is recommended to monitor vital signs when initiating treatment with iloprost in patients at risk.

The sodium phenylacetate in Ammonul has a moderate potential interaction with Liver Disease.

Phenylacetate conjugates with glutamine in the liver and kidneys to form phenylacetylglutamine, via acetylation. Phenylacetylglutamine is excreted by the kidneys via glomerular filtration and tubular secretion. Similarly, preceded by acylation, benzoate conjugates with glycine to form hippuric acid, which is rapidly excreted by the kidneys by glomerular filtration and tubular secretion. It is recommended to use caution and close monitoring when using products containing sodium phenylacetate and sodium benzoate in patients with impaired renal function and in patients with hepatic insufficiency.

The sodium benzoate in Ammonul has a moderate potential interaction with Peptic Ulcer.

Sodium benzoate is structurally similar to salicylates and exacerbation of peptic ulcers may occur. Therapy with sodium benzoate should be administered cautiously in patients with or predisposed to peptic ulcer disease.

The sodium phenylacetate in Ammonul has a moderate potential interaction with Peripheral Neuropathy.

The administration of intravenous phenylacetate may cause neurotoxicity. It is recommended to exercise care when using products containing sodium phenylacetate and sodium benzoate in cancer patients or in patients with neurotoxic disorders.

Iloprost has a moderate potential interaction with Pulmonary Impairment.

Iloprost can induce bronchospasm and may be more severe or frequent in patients with history of hyperreactive airways. Close monitoring is recommended when using iloprost in patients with chronic obstructive pulmonary disease, severe asthma, or with acute pulmonary infections.

The sodium phenylacetate in Ammonul has a moderate potential interaction with Renal Dysfunction.

Phenylacetate conjugates with glutamine in the liver and kidneys to form phenylacetylglutamine, via acetylation. Phenylacetylglutamine is excreted by the kidneys via glomerular filtration and tubular secretion. Similarly, preceded by acylation, benzoate conjugates with glycine to form hippuric acid, which is rapidly excreted by the kidneys by glomerular filtration and tubular secretion. It is recommended to use caution and close monitoring when using products containing sodium phenylacetate and sodium benzoate in patients with impaired renal function and in patients with hepatic insufficiency.

The sodium phenylacetate in Ammonul has a moderate potential interaction with Renal Dysfunction.

The combination product of sodium phenylacetate and sodium benzoate injection 10%/10% contains 30.5 mg of sodium per mL of undiluted product. Sodium phenylacetate and sodium benzoate injection should be used with great care, if at all, in patients with congestive heart failure or severe renal insufficiency, and in clinical states in which there is sodium retention with edema. It is recommended to discontinue administration of sodium phenylacetate and sodium benzoate injection, 10%/10%, evaluate the patient, and institute appropriate therapeutic countermeasures as appropriate.